HCPLive Network

Case Study Identifies B. miyamotoi As Cause of Meningoencephalitis

 
THURSDAY, Jan. 17 (HealthDay News) -- The spirochete, Borrelia miyamotoi, may be an underrecognized cause of meningoencephalitis, according to a case study published in the Jan. 17 issue of the New England Journal of Medicine.

Joseph L. Gugliotta, M.D., of the Robert Wood Johnson Medical School in New Brunswick, N.J., and colleagues report the case of a B. miyamotoi infection-associated meningoencephalitis which developed in an immunocompromised patient.

According to the report, an 80-year-old woman who lived on a farm in New Jersey, who had been treated twice for Lyme Disease and was immunocompromised due to treatment for non-Hodgkin's lymphoma, developed progressive cognitive decline over a four-month period. She was admitted to the hospital and diagnosed with meningoencephalitis. Although Koch's postulates were not met, the woman's illness was posited to be caused by infection with the spirochete B. miyamotoi as the organism was directly detected in cerebrospinal fluid using both microscopy and polymerase chain reaction assay. Following treatment with antibiotics, the patient's physical and mental conditions improved.

"In older persons, changes in mental status are often attributed to dementia or the aging process. Exposure of such persons to diverse microbial agents, including those thought to be nonpathogenic, such as B. miyamotoi, may represent possibilities for pathologic processes to occur," the authors write. "Immunocompromise in older patients should always prompt a more rigorous laboratory analysis, because such persons may serve as sentinels for poorly recognized or novel pathogens."
 

Full Text (subscription or payment may be required)
Letter to the Editor


Copyright © 2013 HealthDay. All rights reserved.
 

Further Reading
Researchers at Hong Kong University and the Wellcome Trust Sanger Institute have identified a link between the influenza A viruses’ genetic diversity and severity of the infection.
Carol Burke, MD, FACG, FASGE, talks about her phase-3 placebo-controlled trial of Celecoxib in pediatric subjects with familial adenomatous polyposis (FAP) at the 2014 ACG Annual Meeting in Philadelphia, PA.
Carol Burke, MD, FACG, FASGE, discusses pediatric familial adenomatous polyposis (FAP) and colorectal cancer at the 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
The immune system is the new focus of much work on traumatic brain injury (TBI). In a challenge to the paradigm that the blood brain barrier prevents harmful leukocytes from entering the brain, a Texas team tried to neutralize the impact of these cells. Peripheral lymphocytes are activated after TBI. They may then act as potential antigen presenting cells and get into the brain, causing cells there to degenerate.
Black women undergoing in vitro fertilization are only about half as likely as white women to become pregnant, and the racial disparity persists even when donor eggs are used. These findings are being presented at the annual meeting of the American Society for Reproductive Medicine, held from Oct. 18 to 22 in Honolulu.
Hospital conversion to for-profit status is associated with improvements in financial margins, but has no effect on process quality metrics or mortality rates, according to a study published in the Oct. 22/29 issue of the Journal of the American Medical Association
Drinking sugar-sweetened sodas may affect cellular aging by shortening telomere length, according to research published online Oct. 16 in the American Journal of Public Health.
More Reading